INTRODUCTION {#S2}
============

Chronic itch or pruritus may arise from dysfunction of skin, immune, nervous system, or internal organ metabolism, such as liver and kidney diseases ([@R26]; [@R50]). Despite recent progress in identifying signaling molecules as potential targets for anti-pruritus therapies ([@R10]; [@R39]), much less is known about the central targets for itch ([@R9]; [@R10]). The mu and kappa opioid receptor systems appear to have opposing roles in a wide range of physiological processes ([@R49]), including itch transmission ([@R7]). Most opioids are pruritogens, and morphine-induced pruritus could be a serious unwanted effect of epidural analgesia ([@R7]; [@R55]). On the other hand, the inhibitory effect of kappa opioid receptor (KOR) agonists, e.g., butorphanol or nalfurafine (TRK-820), on a wide range of itch behaviors has made them attractive drug candidates for treating patients with uremic, cholestatic, and opioid-induced pruritus ([@R19]; [@R33]; [@R36]; [@R51]; [@R65]; [@R73]). KOR-agonist- based anti-pruritic therapies, however, may have unwanted side effects, such as insomnia, somnolence, and constipation ([@R35]; [@R51]). Despite a potential for KOR agonists in anti-itch application, the underlying mechanisms remain poorly understood.

Gastrin-releasing peptide receptor (GRPR) is primarily required for relaying nonhistaminergic itch in the spinal cord ([@R3]; [@R9]; [@R40]; [@R57]; [@R60]; [@R61]). Its endogenous ligand, gastrin-releasing peptide (GRP), is expressed in a subset of dorsal root ganglion (DRG) neurons, which also overlaps with TRPV1 and substance P (SP) ([@R8]; [@R63]; [@R75]). GRP in serum, sensory neurons, and GRPR in the spinal cord of mice, monkeys, and humans with chronic itch were upregulated ([@R17]; [@R28]; [@R41]; [@R46]; [@R64]; [@R66]; [@R75]). A blockade of GRPR or GRP markedly diminishes long-lasting itch in various types of mouse models ([@R34]; [@R57]; [@R75]). These studies raise the question of whether KOR may inhibit itch in part by blocking GRPR function. Consistent with this possibility, studies have shown that spinal KOR activation inhibits GRP-induced scratching (GIS) ([@R29]; [@R37]) and morphine-induced scratching (MIS) ([@R31]; [@R56]).

In this study, we investigated whether spinal KOR activation attenuates itch transmission by blocking GRPR signaling in mice. Using several complementary approaches, we have demonstrated that KOR activation inhibits GRPR signaling via a Ca^2+^-independent phospholipase C (PLC)-protein kinase C (PKC)δ pathway. Our studies may help design spinal KOR-GRPR cross-signaling-based therapeutic strategies to alleviate chronic itch.

RESULTS {#S3}
=======

Spinal KOR Activation Inhibits Nonhistaminergic Itch {#S4}
----------------------------------------------------

To determine the effect of spinal activation of KOR on itch, scratching behavior was quantified in C57BL/6J mice after intrathecal (i.t.) injection of U-50,488, a selective KOR agonist ([@R58]). Consistent with a previous study ([@R27]), U-50,488 significantly attenuated scratching behavior induced by chloroquine (CQ), an anti-malaria drug with generalized pruritus ([@R2]). By contrast, U-50,488 had no effect on histamine-induced scratching ([Figure 1A](#F1){ref-type="fig"}). Consistently, U-50,488 markedly reduced i.t. GIS, whereas scratching behavior elicited by neuromedin B (NMB), a bombesin-related peptide, which is involved in histaminergic itch ([@R68]; [@R77]), was not affected ([Figure 1A](#F1){ref-type="fig"}). The attenuated effect of U-50,488 on GIS and CQ scratching was absent in *Oprk1*^−/−^ mice ([Figure S1A](#SD1){ref-type="supplementary-material"}), indicating that U-50,488 reduced scratching via a KOR-specific manner. There is no difference in scratching behavior induced by GRP or CQ in male versus female mice (data not shown). Furthermore, we observed a significant decrease in CQ-induced scratching after i.t. injection of U-50,488 in female mice ([Figure S1B](#SD1){ref-type="supplementary-material"}), suggesting a lack of sexual dimorphic properties in itch transmission ([@R15]). Finally, we examined the effect of spinal KOR activation on GRPR-dependent chronic itch models ([@R75]). i.t. injection of U-50,488 significantly reduced spontaneous scratching in BRAF^Nav1.8^ mice, a genetic model for chronic itch ([Figure 1B](#F1){ref-type="fig"}). U-50,488 also attenuated chronic itch induced by 2,4-dinitrofluorobenzene (DNFB), a model for allergic contact dermatitis (ACD), and in mice with dry skin itch induced by an acetone-ether-water (AEW) treatment ([@R75]; [Figures 1C and 1D](#F1){ref-type="fig"}). These observations demonstrate that spinal KOR activation inhibits GRPR-dependent acute and chronic itch.

KOR Inhibits GRPR in a Cell-Autonomous Manner {#S5}
---------------------------------------------

The finding that KOR activation inhibited GIS prompted us to examine whether KOR inhibits GIS indirectly through inhibitory neural circuits or directly in GRPR neurons, which are primarily excitatory interneurons ([@R71]). To differentiate between these two possibilities, we first examined whether KOR and GRPR are co-expressed in the spinal cord using dual-labeled RNAscope *in situ* hybridization (ISH) ([@R70]). *Oprk1* mRNA was detected in \~50% (104/205) of *Grpr* neurons in the superficial dorsal horn ([Figures 1E and 1F](#F1){ref-type="fig"}).

The co-expression of KOR and GRPR raised the possibility that KOR activation may cross-inhibit GRPR in a cell-autonomous manner rather than through activation of inhibitory neural circuits. GRPR transduces itch via the PLCβ/IP~3~/Ca^2+^ signaling pathway ([@R40]; [@R76]). To examine this, the dorsal horn of the spinal cord was dissected and dissociated and neurons were cultured for calcium imaging ([Figure 2A](#F2){ref-type="fig"}; [Video S1](#SD2){ref-type="supplementary-material"}). To determine whether U-50,488 inhibits GRP-induced, GRPR-mediated intracellular Ca^2+^ mobilization, a two-step protocol was employed, whereby dissociated dorsal horn GRPR^+^ neurons can be identified by an application of GRP (20 nM) and then re-sensitized after a 30-min wash-out period ([Figure 2C](#F2){ref-type="fig"}; [Table S1](#SD6){ref-type="supplementary-material"}; [@R76]). The ratio of the second GRP-induced response to the first response was used for quantitation, thereby avoiding inconsistencies that may result from GRPR^+^ neuronal heterogeneity. U-50,488 (up to 20 μM) alone did not induce Ca^2+^ responses in GRPR^+^ neurons (data not shown). However, incubation of U-50,488 (10 μM) attenuated Ca^2+^ responses of GRPR^+^ neurons to GRP ([Figures 2B, 2D, and 2F](#F2){ref-type="fig"}; [Video S2](#SD3){ref-type="supplementary-material"}), and this inhibitory effect was reversed by norbinaltorphimine (norBNI), a selective KOR antagonist ([@R53]; [Figures 2E and 2F](#F2){ref-type="fig"}). About 42% of GRPR^+^ neurons showed complete inhibition (52/124) by KOR activation, 26% showed partial inhibition (32/124), and 32% were resistant to U-50,488 application (40/124; [Table S2](#SD6){ref-type="supplementary-material"}). The finding that the percentage of non-responders was slightly lower than *Grpr^+^/Oprk1*^−^ neurons, as observed by RNAscope ISH ([Figures 1E and 1F](#F1){ref-type="fig"}), could be due to several factors, such as younger age of mice used for calcium imaging study and/or different sensitivities associated with each approach. CQ itch is significantly reduced, but not abolished, in *Grpr* KO mice ([@R60]), suggesting the involvement of a GRPR-independent pathway. To test whether U-50,488 may inhibit CQ itch via GRPR-independent pathway, we examined its effect on CQ itch using *Grpr* KO mice and found that i.t. U-50,488 did not further reduce CQ-induced scratching ([Figure S2A](#SD1){ref-type="supplementary-material"}). This result suggests that spinal KOR activation inhibits CQ itch predominantly via GRPR-cell-autonomous mechanism.

Next, we investigated whether KOR activation inhibits GRPR signaling via the canonical opioid-mediated G~αi~ signaling pathway ([@R5]). Unexpectedly, pertussis toxin (PTX) (200 ng/mL), a G~αi~ inhibitor, did not block the inhibitory effect of U-50,488 ([Figure 2G](#F2){ref-type="fig"}), suggesting that a G~αi~-independent pathway is involved in spinal KOR activation-mediated itch inhibition. Of the 23 GRPR neurons treated with PTX, GRP-induced calcium responses in 16/23 (70%) were completely inhibited by U-50,488, 2/23 (9%) showed partial inhibition, whereas 5/23 (21%) were resistant to U-50,488 treatment. As expected, PTX reversed U-50,488-mediated inhibition of cyclic AMP (cAMP) synthesis in HEK293 cells ([Figure S3A](#SD1){ref-type="supplementary-material"}). To test whether KOR may differentially couple to G~αs~ in GRPR-KOR cells, we measured cAMP accumulation and found that neither U-50,488, GRP, nor their co-application induced cAMP accumulation ([Figure S3B](#SD1){ref-type="supplementary-material"}), implying that it is unlikely that a G~αs~-dependent pathway is involved in KOR-GRPR cross-signaling.

According to the canonical pathway, activation of KOR recruits G-protein-coupled receptor kinases (GRK). Arrestin will then bind to the phosphorylated KOR, resulting in acute desensitization ([@R14]). In contrast, U-50,488-mediated desensitization lasts for at least two days in mice ([Figure S1C](#SD1){ref-type="supplementary-material"}). Furthermore, U-50,488 attenuated GIS in *Arrb2*^−/−^ mice ([Figure S3C](#SD1){ref-type="supplementary-material"}), consistent with previous studies ([@R13]; [@R44]). Although we cannot completely exclude the involvement of arrestin signaling, due to possible genetic compensation in *Arrb2*^−/−^ mice, the long-lasting effect of KOR-mediated inhibitory action on itch transmission supports the notion that KOR activation attenuates itch through β-arrestin2 signaling-independent pathway.

Spinal KOR Activation Inhibits GRPR Function via a PKC-Dependent Mechanism {#S6}
--------------------------------------------------------------------------

Previous *in vitro* studies show that GRPR is a substrate of PKC that phosphorylates and desensitizes GRPR ([@R6]). To explore the possibility that PKC activation inhibits itch, scratching behavior was examined in mice pre-injected with i.t. phorbol myristate acetate (PMA), a PKC activator ([@R72]), which markedly attenuated CQ-induced scratching and GIS, mimicking the U-50,488 effect ([Figure 3A](#F3){ref-type="fig"}). Interestingly, bisindolymaleimide (BIM), a selective inhibitor for PKCα, β1, β2, γ, δ, and ε isoforms ([@R67]), blocked the effect of U-50,488 on GIS ([Figure 3B](#F3){ref-type="fig"}). Furthermore, PMA completely blocked spontaneous scratching behavior of BRAF^Nav1.8^ mice, ACD, and dry skin chronic itch mouse models ([Figure 3C](#F3){ref-type="fig"}). These findings raised a possibility that KOR activation suppresses itch via PKC-mediated inhibition of GRPR function.

Next, we examined whether PKC activation could reduce GRP-induced Ca^2+^ responses in GRPR^+^ neurons by applying PMA. Consistent with behavioral studies, PMA significantly attenuated GRP-induced Ca^2+^ responses ([Figures 3D and 3E](#F3){ref-type="fig"}). Co-application of PMA and U-50,488 did not further reduce GRP-induced Ca^2+^ responses, suggesting that KOR activation attenuates GRPR signaling via PKC ([Figures 3D and 3E](#F3){ref-type="fig"}). Moreover, pre-incubation with BIM (5 μM) blocked the inhibitory effect of U-50,488 on Ca^2+^ responses of GRPR^+^ neurons ([Figures 3F and 3G](#F3){ref-type="fig"}). These observations support the notion that KOR activation attenuates itch transmission via PKC-mediated inhibition of spinal GRPR function.

Activation of KOR Induces GRPR Phosphorylation via PKC {#S7}
------------------------------------------------------

Whole-cell phosphorylation assays were performed to further elucidate the role of PKC in KOR-activation-induced inhibition of GRPR signaling. In HEK293 cells expressing FLAG-KOR and Myc-GRPR, GRPR phosphorylation increased 13-fold after a 2-min incubation in U-50,488 (10 μM; [Figures 4A, 4B](#F4){ref-type="fig"}, and [S7A](#SD1){ref-type="supplementary-material"}). Consistent with behavior and calcium-imaging results, PKC inhibition by BIM (5 μM) blocked KOR-activation-induced GRPR phosphorylation ([Figures 4C](#F4){ref-type="fig"} and [S7B](#SD1){ref-type="supplementary-material"}). Rapid GRPR phosphorylation was also observed within 2 min after treatment with PMA (1 μM) and decreased after 15 min ([Figures 4D](#F4){ref-type="fig"} and [S7C](#SD1){ref-type="supplementary-material"}), in accordance with previous findings ([@R6]). Phosphorylation assays showed that U-50,488-mediated KOR activation induces rapid and robust, GRP-independent phosphorylation of GRPR, which may cause desensitization of GRPR activity.

KOR Activation Attenuates Itch via PKCδ {#S8}
---------------------------------------

The PKC family consists of a variety of isoforms that can be classified into three sub-families: conventional (α, β1, β2, and γ; Ca^2+^ and diacylglycerol \[DAG\] dependent); novel (δ, ε, η, and θ; DAG dependent); and atypical (ζand I/λ; [@R47]; [@R59]). Given that U-50,488 failed to induce Ca^2+^ responses in GRPR neurons, we postulated that Ca^2+^-independent PKC isoforms (PKCδ or ε) may be involved in mediating KOR-dependent PKC activation. To identify the PKC isoform involved, we performed spinal PKC-isoform-specific small interfering RNA (siRNA) knockdown studies ([@R40]). Remarkably, siRNA knockdown of *Prkcd* not only blocked U-50,488 inhibition of GIS ([Figure 5A](#F5){ref-type="fig"}) but also enhanced CQ-induced itch, even in the presence of U-50,488 ([Figure 5B](#F5){ref-type="fig"}). Treatment of control siRNA did not affect U-50,488 inhibitory effect on GIS and CQ itch ([Figures S4A and S4B](#SD1){ref-type="supplementary-material"}). qRT-PCR of the lumbar spinal cord confirmed specific knockdown of *Prkcd*, but not *Prkca* ([Figure 5C](#F5){ref-type="fig"}). Consistently, U-50,488 lost effect on GRP-induced calcium responses of dorsal horn neurons isolated from *Prkcd*^−/−^ mice ([Figure S5B](#SD1){ref-type="supplementary-material"}). We also performed siRNA knockdown of *Prkca.* However, U-50,488 attenuated CQ-induced itch after siRNA knockdown of *Prkca*, suggesting that PKCα does not mediate KOR activation inhibition of itch ([Figures S4C and S4D](#SD1){ref-type="supplementary-material"}).

Next, we examined the role of PKCδ in KOR-activation-mediated itch inhibition using *Prkcd*^−/−^ mice and their wild-type (WT) littermates ([@R38]) and did not find differences in GIS between *Prkcd*^−/−^ and WT littermates. As predicted, the inhibitory effect of U-50,488 on GIS is lost in *Prkcd*^−/−^ mice relative to their WT littermates ([Figure 5D](#F5){ref-type="fig"}). To examine whether PKCδ is co-expressed with GRPR in the superficial dorsal horn, we generated a *Grpr*^iCre^/Ai9 reporter mouse line by crossing *Grpr*^iCre^ mice with a tdTomato Ai9 line. Double immunohistochemistry (IHC) studies were conducted, and PKCδ was detected in *Grpr*^iCre^-tdTomato^+^ neurons (arrows indicate overlap in expression; [Figure 5E](#F5){ref-type="fig"}). Further, we labeled spinal GRPR neurons with enhanced yellow fluorescent protein (eYFP) by injection of AAV5-Ef1a-DIO-eYFP virus into the dorsal spinal cord of *Grpr*^iCre^ mice. Consistently, we detected numerous PKCδ in *Grpr*^iCre^; AAV-DIO-eYFP neurons ([Figures 5F](#F5){ref-type="fig"} and [S5A](#SD1){ref-type="supplementary-material"}).

KOR Activation Induces PKCδ Translocation to the Plasma Membrane {#S9}
----------------------------------------------------------------

To further evaluate the role of PKCδ in KOR-activation-induced inhibition of GRPR signaling, we examined PKC translocation from the cytosol to the plasma membrane, a hallmark of PKC activation ([@R43]). Using GFP-tagged PKC, the dynamics of PKC translocation in response to different stimuli can be monitored in live cells and in real time ([@R48]; [@R69]). HEK293 cells expressing KOR and GRPR were transfected with PKCδ-EGFP or PKCα-EGFP. Confocal live-cell imaging was then performed to characterize spatiotemporal properties of PKCδ-EGFP or PKCα-EGFP after application of U-50,488 or PMA. PKCδ and PKCα were present in the cytosol without stimulation ([Figure 6A](#F6){ref-type="fig"}; 0 min). Application of U-50,488 (10 μM) prompted translocation of PKCδ, but not PKCα, to the cell membrane. PKCδ-EGFP translocation from the cytosol to the plasma membrane was apparent as early as 5 min and reached a maximum after 30 min of incubation in U-50,488 ([Figure 6A](#F6){ref-type="fig"}; [Video S3](#SD4){ref-type="supplementary-material"}). After U-50,488 treatment, translocation to the plasma membrane increased significantly (from 15% ± 4% to 62% ± 8%; [Figure 6B](#F6){ref-type="fig"}). As expected, direct activation of PKC with PMA (100 nM) induced translocation of both PKCδ-EGFP and PKCα-EGFP from the cytosol to the membrane ([Figures 6C and 6D](#F6){ref-type="fig"}; [Video S4](#SD5){ref-type="supplementary-material"}).

To evaluate that the U-50,488-induced PKCδ translocation observed in HEK293 cells mimics events *in vivo*, the fraction of PKCδ-positive dorsal horn neurons was quantified 30 min after i.t. injection of U-50,488 in mice. We found that the fraction of dorsal horn neurons with plasma-membrane-bound PKCδ nearly doubled after U-50,488 injection (from 40% ± 1% to 73% ± 2%; [Figures 6E--6G](#F6){ref-type="fig"}). This confirmed that KOR activation stimulates PKCδ activity manifested by its translocation to the plasma membrane, which subsequently phosphorylates and desensitizes GRPR signaling.

KOR Activation Stimulates PKCδ via PLC {#S10}
--------------------------------------

To elucidate the mechanism by which KOR activation stimulates PKCδ, we tested a myriad of inhibitors on U-50,488-induced PKCδ translocation in HEK293 cells expressing KOR and GRPR. Pre-incubation of U73122 (10 μM), a PLC inhibitor, for 10 min blocked U-50,488-induced PKCδ-EGFP translocation to the plasma membrane. In contrast, U-50,488 treatment increased the membrane translocation of PKCδ-EGFP from 12% ± 4% to 64% ± 5% in the presence of U73343 (10 μM), an inactive analog of U73122 ([Figures 7A and 7B](#F7){ref-type="fig"}). Furthermore, U-50,488 treatment increased the translocation of PKCδ-EGFP from 11% ± 2% to 47% ± 5% and 15% ± 3% to 70% ± 9% after a prior pre-incubation in gallein (100 μM), a G~βγ~ inhibitor, and PTX (200 ng/mL), respectively ([Figures 7C and 7D](#F7){ref-type="fig"}), suggesting that PLC mediates PKCδ activation by KOR in a G~βγ~- and G~αi~-independent process. Whole-cell phosphorylation assays were also used to show that KOR activation induces GRPR phosphorylation via PLC. U73122, but not U73343, blocked GRPR phosphorylation ([Figures 7E, 7F](#F7){ref-type="fig"}, and [S7D](#SD1){ref-type="supplementary-material"}). Together, these results suggest that KOR activation stimulates PLC, resulting in the translocation of PKCδ from the cytosol to the plasma membrane, where it phosphorylates GRPR ([Figure 7G](#F7){ref-type="fig"}).

To investigate whether this pathway is similarly engaged by other KOR agonists, we tested butorphanol, a mixed KOR agonist/MOR antagonist ([@R1]), which has been used to treat various types of intractable pruritus in human studies ([@R20]; [@R22]). We found that i.t. injection of butorphanol (2 nmol) significantly reduced CQ-induced scratching behaviors in WT, but not in *Oprk1*^−/−^ mice ([Figure S2B](#SD1){ref-type="supplementary-material"}), suggesting that butorphanol inhibits CQ itch via a KOR-dependent mechanism. Furthermore, i.t. injection of butorphanol (2 nmol) did not further reduce CQ-induced scratching in *Grpr* KO mice ([Figure S2C](#SD1){ref-type="supplementary-material"}). Consistently, butorphanol also lost effect in *Prkcd*^−/−^ mice ([Figure S2D](#SD1){ref-type="supplementary-material"}). These studies provide clinically relevant evidence supporting that spinal KOR-agonists-mediated itch inhibition is dependent on the KOR-GRPR cross-talk, but not other mechanisms. In HEK293 cells expressing KOR and GRPR, butorphanol induced PKCδ-EGFP, but not PKCα-EGFP, translocation from the cytosol to the plasma membrane, mimicking the U-50,488 effect ([Figure S6](#SD1){ref-type="supplementary-material"}). Consistent with U-50,488 and butorphanol results, dynorphin, an endogenous ligand for KOR ([@R16]), also attenuated CQ-induced itch ([Figure S2E](#SD1){ref-type="supplementary-material"}). However, mice lacking dynorphin (*Pdyn*^−/−^) exhibited normal acute and chronic itch ([Figures S2F and S2G](#SD1){ref-type="supplementary-material"}). These data demonstrate that spinal KOR activation by different agonists suppresses itch transmission via PLC-PKCδ pathway and endogenous dynorphin is not required for itch modulation under either normal physiological or chronic itch conditions.

DISCUSSION {#S11}
==========

Using a multidisciplinary and spinal-cord-specific approach, we show that a Ca^2+^-independent KOR-PLC-PKCδ-GRPR pathway is activated in response to KOR agonists, resulting in an attenuation of GRPR function, which is required for development of chronic itch in mice ([@R60]; [@R75]). Consistent with previous findings showing that GRPR is minimally required for histaminergic itch ([@R4]; [@R61]; [@R75]), we show that spinal KOR activation does not impact histaminergic itch, including NMB-mediated scratching behavior ([@R68]; [@R77]). Our data suggest that the anti-histaminergic itch effect elicited by systemic KOR agonists is likely attributable to peripheral KOR ([@R11]; [@R18]; [@R62]; [@R65]). Taken together, these findings illustrate a spinal mechanism by which KOR agonists attenuate itch transmission.

Spinal KOR activation reduces itch transmission by inhibiting the function of GRPR in a cell-autonomous manner in KOR-GRPR neurons. In addition to GRPR excitatory neurons, KOR is also expressed in non-GRPR GABAergic neurons in the spinal cord ([@R74]). Activation of KOR in non-GRPR neurons by KOR agonists could induce thermal analgesia ([@R45]; [@R52]; [@R74]), likely via the G~αi~ signaling pathway ([@R5]; [@R23]; [@R54]). Because of itch and pain antagonism and their distinct neuronal outputs, it is unlikely that inhibition of non-GRPR KOR neurons in the spinal cord would contribute to itch inhibition. Importantly, KOR-agonist-induced anti-itch effect is lost in *Grpr* KO mice, suggesting that GRPR is required for mediating anti-itch effects. The remaining KOR-agonist-resistant scratching effect induced by CQ in *Grpr* KO mice is likely mediated by glutamatergic transmission in *Grpr*^−/−^ neurons that are also required for histaminergic transmission ([@R4]; [@R68]). Taken together, depending on GRPR and neurotransmitter expression, activation of KOR neurons in the spinal cord gives rise to two distinct behavioral outputs: GABAergic KOR neurons compute anti-nociceptive output, whereas excitatory KOR-GRPR neurons convey anti-pruriceptive information ([Figure 7H](#F7){ref-type="fig"}). The dual role of KOR is reminiscent of MOR1 and 5HT1A, which is predominantly implicated in anti-nociceptive signaling, with only a small percentage communicating with GRPR, in contrast to KOR-GRPR, to induce or facilitate itch ([@R40]; [@R76]). Thus, depending on agonists and type of GPCRs, GRPR neurons could serve as a gate to control the output of itch information.

The observation that PTX fails to reverse the effect of U-50,488 demonstrates that KOR signaling via a non-canonic G~αi~-independent pathway, is specific to KOR-GRPR excitatory neurons. The finding that KOR-activation-mediated signal transduction is independent of G~βγ~ protein as well as G~αs~ protein suggests that KOR may activate PLC independent of G protein. How could KOR activate PKCδ, but not PLCβ, which acts downstream of GRPR ([@R40]), in GRPR neurons? It is possible that KOR activation selectively recruits PKCδ to phosphorylate GRPR, thereby dampening PLCβ signaling via a competitive manner ([Figure 7G](#F7){ref-type="fig"}). It is also likely that the presence of a GRPR-KOR heteromeric complex switches the downstream signaling kinase cascade of canonic KOR pathway to occlude PLCβ activation.

One remarkable finding is that Ca^2+^-independent PKCδ activation via membrane translocation provides a major mechanism by which GRPR is phosphorylated and desensitized. Importantly, behavioral studies indicate that PKCδ-mediated desensitization of GRPR is long lasting. Previous *in vitro* studies suggested that the classic GRPR-PLC-IP~3~ Ca^2+^ signaling activates kinases other than PKC ([@R32]), and GRPR agonist-induced Ca^2+^-dependent desensitization is transient and lasts less than 2 min ([@R76]). It is possible that distinct phosphorylation sites at the C-terminal domain of GRPR may contribute to the duration of desensitization ([@R6]). Whether PKCδ desensitizes agonist-unoccupied GRPR via direct phosphorylation or indirectly via other kinases awaits further studies ([@R30]). Direct examination of spinal GRPR phosphorylation levels after KOR activation requires an antibody that can specifically detect phosphorylated GRPR *in vivo*, which contains multiple potential phosphorylation sites on its C terminus ([@R6]). Several lines of evidence fail to support the view that the endogenous dynorphin is an important modulator of itch transmission ([@R29]): first, consistent with previous studies using either *Pdyn* KO mice or ablation of spinal Dyn^+^ neurons ([@R21]; [@R29]), *Pdyn* KO mice showed normal acute and chronic itch behaviors. Second, KOR agonists attenuate GRPR function via a long-lasting phosphorylation rather than acute desensitization process, the former of which rarely occurs under normal physiological condition. These observations are in support of the notion that KOR-GRPR cross-signaling induced by exogenous KOR agonists reflects an artificial process. While there is no evidence that the endogenous dynorphin modulates itch in normal physiological context, the possibility that a dramatic down-regulation of *Pdyn* in chronic itch condition (data not shown) may suggest an attenuation of inhibitory circuit cannot be excluded.

In summary, we demonstrate a non-canonical opioid signaling mechanism by which GRPR activity is attenuated by KOR-mediated cross-signaling in the spinal cord of mice. The finding of the inhibitory effect of KOR activation and its downstream signaling components on distinct types of chronic itch (BRAF^Nav1.8^, ACD, and AEW) suggests a possibility for a broader application of KOR-GRPR-based anti-itch strategy to the treatment of chronic itch with various etiologies.

EXPERIMENTAL PROCEDURES {#S12}
=======================

Animals {#S13}
-------

Behavioral tests were carried out on C57BL/6J, *Oprk1*^−/−^ ([@R25]), *Grpr* KO ([@R24]), BRAF^Nav1.8^ ([@R75]), *Grpr*^iCre^, Ai9 (MMRRC), *Arrb2*^−/−^ ([@R12]), and *Prkcd*^−/−^ ([@R38]) male mice and their WT littermates unless indicated otherwise. All experiments conform to guidelines set by the NIH and the International Association for the Study of Pain and were reviewed and approved by the Animal Studies Committee at Washington University School of Medicine.

Itch Behavior {#S14}
-------------

Mice were individually put into observation boxes and videotaped. The videos were played back on a computer and quantified by an observer who was blinded to the treatment or mice genotype. A scratch is defined as a bout of scratching that occurs after the mouse lifts its hind paw to the moment the hind paw is returned to the ground or mouth ([@R60]). For the dry-skin model, mice were painted twice daily with a mixture of acetone and diethyl ether (1:1) followed by water. Scratching behavior directed at the neck was counted in the morning before treatment ([@R42]; [@R75]). For ACD model, mice were sensitized by applying 100 μL of 0.15% DNFB on abdominal skin. One week later, mice were challenged by nape application of 50 μL of 0.15% DNFB every 2 or 3 days. Scratching responses were measured 24 hr after applying DNFB ([@R75]).

RNAscope *In Situ* Hybridization and Immunohistochemistry {#S15}
---------------------------------------------------------

RNAscope ISH and IHC staining were performed as described ([@R70]; [@R76]). Spinal sections were processed according to the manufacturer's instructions in the RNAscope Fluorescent Multiplex Assay v2 manual for fixed frozen tissue (Advanced Cell Diagnostics).

siRNA Studies {#S16}
-------------

*Prkcd* siRNA (Sigma) was delivered to the lumbar region of the spinal cord via i.t. injection as described ([@R40]; [@R76]). Mice were injected twice daily for 3 consecutive days, and behavior was performed 24 hr after the last injection.

Dissociation of Dorsal Horn Neurons and Calcium Imaging {#S17}
-------------------------------------------------------

Primary culture of spinal dorsal horn neurons was prepared from 5- to 7-day-old C57BL/6J mice and seeded onto 12-mm coverslips coated with poly-D-lysine. Calcium imaging was performed 3--5 days after seeding as described previously ([@R76]).

Whole-Cell Phosphorylation Assay {#S18}
--------------------------------

HEK293 cells expressing FLAG-KOR and Myc-GRPR were incubated in 10 μM U-50,488 or 1 μM PMA at 37°C and lysed as described ([@R40]). Proteins were incubated with mouse anti-Myc antibody (Sigma) overnight. The complex was precipitated, resolved on polyacrylamide gels, and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore). Proteins were detected by immunoblotting with mouse anti-phosphoserine antibody (1:2,500; Sigma) overnight, and the blot was developed by enhanced chemiluminescence (Thermo Scientific).

PKC Translocation Assay {#S19}
-----------------------

KOR-GRPR HEK293 cells, transiently expressing PKCδ-EGFP or PKCα-EGFP (kindly provided by Dr. Peter M. Blumbergtaken) were seeded in 29-mm glass bottom dishes (*In Vitro* Scientific). After 24 hr, the subcellular distribution of EGFP-fused protein was analyzed on a Leica TCS SPE confocal microscope.

Statistical Analysis {#S20}
--------------------

Statistical comparisons were performed with Graphpad Prism 7. Groups were considered significantly different if p \< 0.05. Results are presented as the mean ± SEM.

Supplementary Material {#S22}
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![Intrathecal Administration of U-50,488 Attenuates Nonhistaminergic Itch\
(A) 10-min pre-injection of U-50,488 (10 nmol) significantly reduced scratching induced by CQ (200 μg intradermal \[i.d.\]) and GRP (0.3 nmol i.t.), but not Hist (200 μg i.d.) and NMB (1 nmol i.t.; \*p \< 0.05; \*\*\*p \< 0.001; Student's unpaired t test; n = 6--11).\
(B--D) Reduced spontaneous scratching in (B) BRAF^Nav1.8^, (C) ACD, and (D) dry-skin mice after U-50,488 injection (\*p \< 0.05; \*\*\*p \< 0.001; Student's paired t test; n = 7--9).\
(E) Representative images of RNAscope *in situ* hybridization of *Grpr* (green) and *Oprk1* (red) mRNA expression in superficial dorsal horn of transverse lumbar sections. Arrows indicate double-stained neurons. Blue represents DAPI nucleic acid stain (scale bar, 20 μm).\
(F) Venn diagram showing the overlap in expression of *Grpr* and *Oprk1* in dorsal horn neurons (n = 20 lumbar sections from 3 mice). Data are represented as mean ± SEM.\
See also [Figures S1 and S2](#SD1){ref-type="supplementary-material"}.](nihms962085f1){#F1}

![Activation of KOR Inhibits GRPR Ca^2+^ Signaling in Dorsal Horn Neurons\
(A) Schematic showing dissection of the spinal cord, seeding, and culture of dissociated dorsal horn neurons.\
(B) Ratiometric fluorescence images of dissociated GRPR neurons showing changes in calcium after adding 20 nM GRP (62--124 s). After a wash-out period, a 2- min pretreatment with 10 μM U-50,488 inhibited GRP-induced Ca^2+^ responses in GRPR neurons (1,880--1,940 s).\
(C) Representative traces showing that GRP-induced calcium responses completely recovered after a 30-min wash-out period.\
(D) U-50,488 inhibited GRP-induced Ca^2+^ responses in dissociated dorsal horn neurons.\
(E) 10-min pretreatment with 10 μM norBNI blocked the U-50,488 inhibitory effect on GRP-induced Ca^2+^ responses.\
(F) Quantified data comparing peak intracellular concentration evoked by GRP after pretreatment with U-50,488 (red) or norBNI+U-50,488 (purple; \*\*\*p \< 0.001; one way ANOVA followed by Tukey's multiple comparison test; n = 11--27).\
(G) PTX (200 ng/mL) had no effect on U-50,488 inhibitory effect on GRP-induced Ca^2+^ responses (\*\*p \< 0.01; NS, not significant; one way ANOVA followed by Tukey's multiple comparison test; n = 26--49).\
Data are represented as mean ± SEM. See also [Figures S2 and S3](#SD1){ref-type="supplementary-material"}.](nihms962085f2){#F2}

![PKC Inhibition in the Spinal Cord Blocks KOR-Activation-Induced Attenuation of Itch\
(A) Pre-injection of PMA (1 nmol i.t.) significantly reduced scratching induced by GRP and CQ (\*\*p \< 0.01; \*\*\*p \<0.001; Student's unpaired t test; n=6--8).\
(B) BIM (40 pmol i.t.), blocked U-50,488 inhibitory effect on GRP-induced scratching (\*p \< 0.05; \*\*p \< 0.01; one-way ANOVA followed by Tukey's multiple comparison test; n = 9--12).\
(C) PMA (1 nmol) inhibited spontaneous scratching in BRAF^Nav1.8^, ACD, and dry-skin mice (\*\*\*p \< 0.001; Student's paired t test; n = 7--9).\
(D and E) Representative traces (D) and quantified data (E) show that PMA (1 μM) inhibitsGRP-induced Ca^2+^ responses in dissociated GRPR neurons (\*\*\*p \< 0.001; Student's unpaired t test; n = 12). The inhibitory effect was no further reduced by co-application of PMA (1 μM) and U-50,488 (10 μM; \*\*\*p \< 0.001; Student's unpaired t test; n = 15).\
(F and G) BIM (5 μM) blocked U-50,488 inhibitory effect on GRP-induced Ca^2+^ responses (\*\*\*p \< 0.001; Student's unpaired t test; n = 43--65).\
Data are represented as mean ± SEM.](nihms962085f3){#F3}

![Activation of KOR Induces GRPR Phosphorylation via PKC\
(A and B) Western blots (A) and quantified data (B) showing that U-50,488 induced robust GRPR phosphorylation after 2 min in HEK293 cells expressing KOR and GRPR (\*\*p \< 0.01 Student's paired t test; n = 4).\
(C) BIM (5 μM) blocked U-50,488-induced phosphorylation of GRPR (n = 4).\
(D) Time course analysis of PMA (1 μM)-induced GRPR phosphorylation in HEK293 cells.\
Data are represented as mean ± SEM. See also [Figure S7](#SD1){ref-type="supplementary-material"}.](nihms962085f4){#F4}

![U-50,488 Attenuates Itch via PKCδ\
(A and B) U-50,488 failed to block scratching induced by (A) GRP (0.06 nmol i.t.) and (B) CQ (100 μg i.d.) in *Prkcd* siRNA-treated mice (\*p \< 0.05; one way ANOVA followed by Tukey's multiple comparison test; n = 7).\
(C) qRT-PCR showed that the level of spinal *Prkcd* mRNA was significantly reduced by *Prkcd* siRNA injection, whereas the *Prkca* mRNA level was not affected (\*p \< 0.05; Student's unpaired t test; n = 4).\
(D) U-50,488 failed to block scratching induced by GRP (0.3 nmol i.t.) in *Prkcd*^−/−^ mice (\*p \< 0.05; \*\*p \< 0.01; Student's unpaired and paired t test; basal relative to U-50; n = 7--9).\
(E) Double IHC of tdTomato (red) and PKCδ (green) shows co-expression of GRPR and PKCδ in superficial dorsal horn neurons.\
(F) Double IHC of PKCδ (purple) and eYFP (green) shows co-expression of GRPR and PKCδ in superficial dorsal horn neurons of *Grpr*-iCre mice injected with AAV-DIO-eYFP. Arrows indicate double- stained cells. The scale bar represents 10 μm.\
Data are represented as mean ± SEM. See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms962085f5){#F5}

![KOR Activation Induces Translocation of PKCδ, but Not PKC~α~, to the Plasma Membrane\
(A) HEK293 cells expressing KOR/GRPR transfected with PKCδ-EGFP (upper row) and PKCα-EGFP (lower row) were incubated in 10 μM U-50,488. Confocal images taken at indicated time points showed that U-50,488 induced the translocation of PKCδ-EGFP, but not PKCα-EGFP, to the plasma membrane (scale bar, 20 μm).\
(B) Percentage of PKCδ-EGFP and PKCα-EGFP translocation to the plasma membrane in response to U-50,488 (\*\*p \< 0.01; Student's paired t test; n = 3--4 cells per experiment).\
(C) 100 nM PMA incubation induced the translocation of both PKCδ-EGFP and PKCα-EGFP to the plasma membrane.\
(D) Percentage of PKCδ-EGFP and PKCα-EGFP translocation to the plasma membrane in response to PMA (\*p \< 0.05; \*\*p \< 0.01; Student's paired t test; n = 3--4 cells per experiment).\
(E) IHC image shows that PKCδ (red) is mostly distributed in the cytosol of superficial dorsal horn neurons of control mouse (upper row). After U-50,488 injection, PKCδ translocates to the plasma membrane (lower row). Arrows show neurons with PKCδ distributed at the plasma membrane (scale bar, 20 μm).\
(F) High-power images of the boxed regions in (E; scale bar, 5 μm; blue, NeuN).\
(G) Percentage of PKCδ translocation to the plasma membrane after U-50,488 injection relative to control in dorsal horn neurons (\*\*\*p \< 0.001; Student's unpaired t test; n = 18 lumbar sections from 3 mice).\
Data are represented as mean ± SEM. See also [Figure S6](#SD1){ref-type="supplementary-material"}.](nihms962085f6){#F6}

![PLC Mediates KOR-Activation- Induced Translocation of PKCδ to the Plasma Membrane\
(A--D) Confocal images (A and C) and quantified data (B and D) showing U-50,488 induced translocation of PKCδ-eGFP from the cytosol to the plasma membrane was blocked by 10 μM U73122 (PLC inhibitor) (A and B). U73343 (inactive analog of U73122) (A and B), 100 μMgallein (G~bg~ inhibitor), and 200 ng/mL PTX (G~αi~ inhibitor; C and D) had no effect on U-50,488-induced translocation of PKCδ-eGFP (n = 3--4 cells per experiment; \*p \< 0.05; Student's paired t test in B; one-way ANOVA followed by Dunnett's multiple comparison test).\
(E and F) Western blots (E) and quantified data (F) showing that U-50,488-induced GRPR phosphorylation is blocked by U73122, but not U73343. Data are represented as mean ± SEM. See also [Figure S5](#SD1){ref-type="supplementary-material"}.\
(G) Schematic showing signaling events by which KOR activation results in GRPR desensitization. KOR activation by U-50,488 stimulates PLC to hydrolyze PIP~2~ into DAG, which in turn induces PKCδ translocation from the cytosol to the plasma membrane, resulting in GRPR phosphorylation and desensitization.\
(H) Schematic illustrates concurrent activation of two distinct subpopulations of dorsal horn interneurons by U-50,488: activation of KOR neurons without GRPR mediates anti-nociceptive output, whereas activation of KOR/GRPR neurons inhibits itch.](nihms962085f7){#F7}

###### Highlights

-   KOR inhibits itch by attenuating GRPR function

-   KOR-GRPR cross-talk is independent of G~αi~ signaling

-   KOR desensitizes GRPR via PKCδ translocation

-   KOR activates PKCδ translocation via PLC signaling
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